Core Insights - Citius Pharmaceuticals successfully launched LYMPHIR, a novel cancer immunotherapy, in December 2025, marking a significant advancement in treatment options for cutaneous T-cell lymphoma (CTCL) patients [2][5][7] Business Highlights - The launch of LYMPHIR represents the first new systemic therapy for CTCL since 2018, showcasing the company's commitment to providing impactful treatments [2] - Citius Pharma has engaged with the FDA to advance other products, including Mino-Lok, and is exploring additional indications for LYMPHIR [2][5] - The company has secured distribution agreements with three leading U.S. pharmaceutical wholesalers and access to LYMPHIR in 19 international markets [5] - LYMPHIR has been included in the National Comprehensive Cancer Network (NCCN) guidelines with a Category 2A recommendation, facilitating coverage and reimbursement [5] Financial Highlights - Citius Pharma raised approximately $61 million in gross proceeds from capital raises, with $25 million from strategic financings for Citius Pharma and $36 million for Citius Oncology [5] - As of September 30, 2025, the company reported cash and cash equivalents of $4.3 million, with no revenues reported for the fiscal year [5][6] - Research and development expenses decreased to $9.2 million from $11.9 million in the previous year, while general and administrative expenses slightly increased to $18.5 million [5][6] - The net loss for the fiscal year was $39.7 million, or $3.38 per share, compared to a net loss of $40.2 million, or $5.97 per share, in the previous year [6][13] Market Potential - The initial market for LYMPHIR is estimated to exceed $400 million and is considered underserved by existing therapies, indicating significant growth potential [7] - The company holds robust intellectual property protections, including orphan drug designation and pending patents, which enhance its competitive positioning in the oncology market [7]